Skip to main content
OpenTrials
Completed

NCT Number: NCT02643693

User Acceptability of a Nicotine Lactate Delivery System (P3L)

This study will provide an initial assessment of the acceptability of the Nicotine Lactate Delivery System (P3L) after ad libitum use and the ability of combustible cigarette (CC) smokers to use P3L to maintain their customary nicotine intake, in a manner comparable with their own brand of CC or the VUSE e-cigarette system.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Smoking Behavior Vaping

Age range

19 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Rose Research Center, LLC

Raleigh, North Carolina, 27617, United States

About this study

The total duration of the study for an individual subject will be between 3 and 8 weeks, including 1 day for the screening visit, 3 days for the ad libitum use sessions (P3L, VUSE e-cigarette system and subjects' own commercially available non-menthol CC), 1 day for the preference evaluation session (subjects will be given the choice of using ad libitum the P3L or the VUSE), the 2 to 10 days of interval between each visit, and 7 days for the passive safety follow-up period.

The pharmacokinetics (PK) and pharmacodynamics (PD, i.e., subjective effects) profiles, will be evaluated as well as the safety and tolerability of the P3L.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Smoking, healthy subject as judged by the Investigator
  • Subject smoked at least 10 commercially available non-menthol CCs per day for the last 12 months
  • Subject does not plan to quit smoking in the next 60 days

Exclusion criteria

  • As per Investigator judgment, the subject cannot participate in the study for any reason (e.g., medical, psychiatric, and/or social reason)
  • Subject has donated or been in receipt of whole blood or blood products within 3 months prior to the screening visit
  • Subject has used tobacco products or nicotine containing products other than CCs within 30 days prior to the screening visit
  • Female subject is pregnant or breast feeding
  • Female subject does not agree to use an acceptable method of effective contraception
  • Female subject uses estrogen-containing hormonal contraception or hormone replacement therapy

Treatment and study plan

P3L

Other

Ad libitum use for a maximum of three hours.

P3L delivers, on average, 80 µg of nicotine per puff under Health Canada Intense smoking regime.

VUSE

Other

Ad libitum use for a maximum of three hours.

VUSE delivers, on average, 80 µg of nicotine per puff based on the CORESTA e-cigarette recommended smoking regime.

CC

Other

Ad libitum use of the subject's own brand of non-menthol CC for a maximum of three hours.

Primary outcomes

  1. Change From Baseline Plasma Concentration of Nicotine/Cotinine After Each ad Libitum Use Session.

    Time frame: Measured at 15 minutes and 5 minutes prior to each 3 hour product use to provide baseline measures, then at 15 minutes and 30 minutes after product use period to show change from baseline.

    For each ad libitum use session (P3L, VUSE, and CC), change from baseline plasma concentration of Nicotine/Cotinine was measured from two blood samples collected before product use (to provide baseline measures) and from two blood samples collected following product use (to show change from baseline).

  2. Overall Score of the Short Version of the Questionnaire of Smoking Urges (QSU-brief). Total Score; Factor 1 (Reward); Factor 2 (Relief)

    Time frame: QSU-brief questionnaire completed before product use session, then at 60 mins, 120 mins, and 180 mins after starting each product use session.

    The QSU-Brief questionnaire is an instrument used to measure urge to smoke. Subjects were asked to respond to 10 questions, scored from 1 to 7 on a 7-point scale. A score of 1 on this scale indicates a very low urge to smoke, while a score of 7 indicates a very high urge to smoke. Subjects were asked to complete the questionnaire before, during, and after each ad libitum product use session. (P3L, VUSE, and Subjects' Own Brand of Non-menthol CC).

    Two factor scores and a total score were derived. Factor 1 represents the desire and intention to smoke with smoking perceived as rewarding, while Factor 2 represents an anticipation of relief from negative effect with an urgent desire to smoke.

    Products were compared over all timepoints using a repeated measure model using values after t0.

    The model adjusted for baseline value, sequence, and period with repeated measure over time and a random effect in subjects. Adjusted mean over all timepoints, for each timepoint, were estimated.

Sponsors and collaborators

Lead sponsor

Philip Morris Products S.A.

Industry

Registry information

Official study title

User Acceptability of a Nicotine Lactate Delivery System Relative to the VUSE e-Cigarette System and Combustible Cigarette Comparators

Important dates

Study start
2015
Primary completion
2016
Study completion
2016
First posted
Dec 31, 2015
Registry last updated
Aug 1, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.